Photonics Industry & Technology Development Association (PIDA) announced yesterday (20 July) that the sector hit a TWD420bn milestone in Q2 2021, with the growth rate up 8.2% QoQ and 20.1% YoY, respectively. Overall the sector ended in the first half of 2021 with TWD$808bn, an annual increase of 26.4%.
As per PIDA, the growth was primarily due to a slowdown in the coronavirus transmission, revival of the global economy and worldwide stimulus programmes for industry. Adding to that, the pricing and demands of flat panel displays had soared as a result of shortage of raw materials and stay-at-home economy. Flat panel monitors, amongst all the other photonic products, contributed largely in H1 to nearly TWD$530bn, up by 36.4% YoY.
See related Taiwan business watch 2020: Biomedical Photonics
Others being benefited from an increase of 20% in revenue were image sensors and biomedical photonic products, with the former in rising demands for smartphones and systems related to 3D imaging for face identification, Time of Flight (ToF) and self-driving vehicles, and the later owing to pandemic prevention. Image sensors alone generated TWD$9bn in H1, 2021, up 26.7% YoY, biomedical photonic products netted TWD$31.8bn, up 22.5% YoY.
Going forward, investment across the world in 5G, AI, remote services, automotive and so on, would grease the wheel of laser, optical communication and optic lenses, PIDA envisioned. On top of that, flat panels, LED lighting, solar photovoltaic and precision optical are expected to thrive following a hectic market for green power, Mini/Micro LED and a new cycle of smartphone replacement.
PIDA has organised several events and activities in H2 to promote the industry- The Optics & Photonic Forum later in August, trade fair OPTO Taiwan on 20-22 October, which will tie with seminars, courses and B2B sessions on topics ranging from silicon photonics, green technology to compound semiconductors.
Source: news.cnyes.com
Previous DKSH partners with life science innovator Nicoya in Asia
Next EirGenix Achieves the Fourth Milestone of Its Trastuzumab Biosimilar Licensing Agreement
Return to the news list
